Department of Cardiovascular Medicine, Arao Municipal Hospital, Arao, Japan.
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Cardiovasc Interv Ther. 2023 Jul;38(3):299-308. doi: 10.1007/s12928-023-00920-3. Epub 2023 Mar 6.
Although the Japanese high bleeding risk criteria (J-HBR) were established to predict bleeding risk in patients undergoing percutaneous coronary intervention (PCI), the thrombogenicity in the J-HBR status remains unknown. Here, we examined the relationships among J-HBR status, thrombogenicity and bleeding events. This study was a retrospective analysis of 300 consecutive patients who underwent PCI. Blood samples obtained on the day of PCI were used in the total thrombus-formation analysis system (T-TAS) to investigate the thrombus-formation area under the curve (AUC; PL-AUC for platelet chip; AR-AUC for atheroma chip). The J-HBR score was calculated by adding 1 point for any major criterion and 0.5 point for any minor criterion. We assigned patients to three groups based on J-HBR status: a J-HBR-negative group (n = 80), a low score J-HBR-positive group (positive/low, n = 109), and a high score J-HBR-positive group (positive/high, n = 111). The primary end point was the 1-year incidence of bleeding events defined by the Bleeding Academic Research Consortium types 2, 3, or 5. Both PL-AUC and AR-AUC levels were lower in the J-HBR-positive/high group than the negative group. Kaplan-Meier analysis showed worse 1-year bleeding event-free survival in the J-HBR-positive/high group compared with the negative group. In addition, both T-TAS levels in J-HBR positivity were lower in those with bleeding events than in those without bleeding events. In multivariate Cox regression analyses, the J-HBR-positive/high status was significantly associated with 1-year bleeding events. In conclusion, the J-HBR-positive/high status could reflect low thrombogenicity as measured by T-TAS and high bleeding risk in patients undergoing PCI.
尽管日本高出血风险标准(J-HBR)是为了预测经皮冠状动脉介入治疗(PCI)患者的出血风险而建立的,但 J-HBR 状态下的血栓形成性仍不清楚。在这里,我们研究了 J-HBR 状态、血栓形成性和出血事件之间的关系。这项研究是对 300 例连续接受 PCI 的患者进行的回顾性分析。在 PCI 当天采集的血液样本用于全血栓形成分析系统(T-TAS),以研究血小板芯片下的血栓形成面积(PL-AUC;血小板芯片的 PL-AUC;动脉粥样硬化斑块芯片的 AR-AUC)。J-HBR 评分通过在任何主要标准上加 1 分和任何次要标准上加 0.5 分来计算。我们根据 J-HBR 状态将患者分为三组:J-HBR 阴性组(n=80)、低评分 J-HBR 阳性组(阳性/低,n=109)和高评分 J-HBR 阳性组(阳性/高,n=111)。主要终点是由 Bleeding Academic Research Consortium 类型 2、3 或 5 定义的 1 年出血事件发生率。PL-AUC 和 AR-AUC 水平在 J-HBR 阳性/高组均低于阴性组。Kaplan-Meier 分析显示,J-HBR 阳性/高组 1 年出血事件无复发生存率较阴性组差。此外,J-HBR 阳性患者的 T-TAS 水平也低于出血事件患者。多变量 Cox 回归分析显示,J-HBR 阳性/高状态与 1 年出血事件显著相关。总之,J-HBR 阳性/高状态可反映 T-TAS 测量的低血栓形成性和 PCI 患者的高出血风险。